At a glance
- Originator SYGNIS Pharma
- Developer Dura Pharmaceuticals; SYGNIS Pharma
- Class Peptides
- Mechanism of Action Immunomodulators; Interleukin 10 stimulants; Melanocortin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chemotherapy-induced damage; Inflammation; Obesity; Postoperative pain; Type 2 diabetes mellitus
Most Recent Events
- 13 Aug 2002 Discontinued - Phase-I for Asthma in USA (Inhalation)
- 13 Aug 2002 Discontinued - Phase-I for Inflammation in USA (Inhalation)
- 13 Aug 2002 Discontinued - Phase-II for Inflammation in USA (unspecified route)